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Abstract
The pathology of Alzheimer's disease (AD) is characterized by cerebral atrophy in frontal,
temporal, and parietal regions, with senile plaques, dystrophic neurites, and neurofibrillar tangles
within defined areas of the brain. Another characteristic of AD is regional hypometabolism in the
brain. This decline in cerebral glucose metabolism occurs before pathology and symptoms manifest,
continues as symptoms progress, and is more severe than that of normal aging. Ketone bodies are
an efficient alternative fuel for cells that are unable to metabolize glucose or are 'starved' of glucose.
AC-1202 is designed to elevate serum ketone levels safely. We previously showed that treatment
with AC-1202 in patients with mild-to-moderate AD improves memory and cognition. Treatment
outcomes were influenced by apolipoprotein E genotype status. These data suggest that AC-1202
may be an effective treatment for cognitive dysfunction by providing an alternative substrate for
use by glucose-compromised neurons.
Background
Hypometabolism in Alzheimer's disease
The human brain is among the most metabolically active
organs in the body and requires large amounts of energy
for proper function. Despite high energy demands, the
brain is relatively inflexible in its ability to utilize sub-
strates for energy production. Under normal conditions
glucose is the primary fuel for the brain, whereas the con-
tribution made by fatty acids is considered minor. The
brain uses approximately 16% of the total oxygen con-
sumed. This is remarkable because the brain accounts for
only about 2% of total body mass. Most of the oxygen is
used for aerobic oxidation of glucose to carbon dioxide
and water.
The dependence on glucose puts the brain at risk for
declines in cognitive function if the supply of glucose is
interrupted, or if defects in the ability to metabolize glu-
cose occur. For example, sudden bouts of hypoglycemia
cause cognitive dysfunction, including sensory distur-
bances and memory defects. Disturbances in the cerebral
metabolic rate of glucose (CMRglu) were an early obser-
vation in Alzheimer's disease (AD). In 1983, de Leon and
coworkers [1] examined 24 elderly patients (mean age 73
years) with senile dementia and observed declines of 17%
to 24% in regional CMRglu. The decreases in glucose use
also correlated with cognitive performance, suggesting
that such declines were a reliable marker of disease status.
Subsequent studies have confirmed regional declines in
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CMRglu as an early and progressive characteristic of AD
[2-4].
One obvious explanation for reductions in CMRglu in AD
patients is simply the large-scale neuronal loss that is a
hallmark of the disease. However, several authors have
examined the earliest occurrence of these defects in people
at risk for AD. In 1996, Reiman and colleagues [5] exam-
ined CMRglu in cognitively normal people who were at
high risk for developing AD. These individuals (average
age 55.4 years) were homozygous for the ε4 allele (E4) of
the apolipoprotein E (ApoE) gene, and had a family his-
tory of AD. The authors used [18F]-fluorodeoxyglucose
positron emission tomography (FDG-PET) to examine
glucose metabolism in the brain. The authors found that
the E4 homozygotes were cognitively normal but had sig-
nificantly reduced rates of glucose metabolism in the
same posterior cingulate, parietal, temporal, and prefron-
tal regions as in previously studied patients with probable
AD. A 2-year follow up revealed that these patients had
greater declines in CMRglu than control individuals [6].
To characterize further the onset of glucose reductions,
Reiman and coworkers [7] recruited young adult E4 carri-
ers and compared them by FDG-PET with individually
matched (sex, age, and educational level) E4 noncarriers.
All of the participants (average age 30.7 years) were cogni-
tively normal and did not differ on a battery of neuropsy-
chological scores. They did, however, differ in terms of
regional CMRglu; E4-positive individuals had abnormally
low rates of glucose metabolism bilaterally in the poste-
rior cingulate, parietal, temporal, and prefrontal cortex.
The reduced rates of CMRglu were not of the magnitude
seen in AD, but they reproduced the typical AD pattern.
The declines in cerebral glucose metabolism are not lim-
ited to carriers of the E4 allele. Early studies examining the
role of ApoE4 on cerebral glucose metabolism largely con-
cluded that the presence of E4 was not a factor in the mag-
nitude of CMRglu reduction [8-10]. However, more recent
studies suggest that the presence of an E4 allele may
impair glucose metabolism more globally [11].
Therefore, it appears that glucose hypometabolism occurs
in at-risk individuals decades before clinical symptoms of
dementia are evident, and is unlikely to be due to cell loss.
This has been examined in carriers of presenilin 1 muta-
tions in cases of early-onset AD. Asymptomatic, individu-
als at-risk for early-onset AD were examined by magnetic
resonance imaging and FDG-PET, and compared with
normal matched control individuals [12]. Extensive
reductions in CMRglu were found in the presymptomatic
early-onset AD individuals in the absence of structural
brain atrophy, suggesting again that cell loss is not a gross
contributor to low FDG-PET signals. Because the cause of
regional decreased glucose metabolism appeared not to
be a simple artifact of cell atrophy, other mechanistic
causes have been investigated. Amyloid β (Aβ), amyloid
precursor protein (APP), and ApoE4 have been examined
for their effects on neuronal metabolism. The reader is
referred to the paper by Atamna and Frey [13] for a discus-
sion of Aβ and mitochondrial dysfunction in AD; that by
Mahley and coworkers [14] for a discussion of the roles
played by fragmented ApoE4 and mitochondrial dysfunc-
tion; and that by Stokin and Goldstein [15] for a discus-
sion of the role played by APP in axonal transport and AD.
Although the toxic effects of ApoE4 fragments, or Aβ pro-
tofibrils, may offer mechanistic explanations for reduced
CMRglu, other evidence suggests that disturbances in the
insulin-lipid-glucose axis may be central to the etiology of
AD, and lead to the characteristic hypometabolism. In
2004, we identified a series of factors that may give rise to
the characteristic pathology in AD. Two major factors
were proposed to explain the clinical and pathological
course of AD: disturbances in lipid metabolism within the
central nervous system (CNS) inhibits the function of
membrane proteins, for example glucose transporters and
APP; and prolonged, excessive insulin/insulin-like growth
factor signaling accelerates cellular damage in neurons.
For a detailed discussion, see Henderson and coworkers
[16].
Other authors have also proposed a link between distur-
bances in the insulin signal transduction pathway and
AD. Hoyer [17] proposed that the downstream effects that
occur due to hypometabolism include diminished pro-
duction of acetyl-coenzyme A (CoA) and ATP, both of
which are necessary for synaptic activity and plasticity.
Acetylcholine synthesis depends on the availability of
acetyl-CoA (provided from glucose breakdown) and insu-
lin (controls the activity of acetylcholine transferase). The
reduced availability of ATP may also damage the endo-
plasmic reticulum and the Golgi/trans-Golgi networks,
producing misfolded proteins within the cell. Further-
more, the trafficking of APP is controlled by insulin and
insulin receptor function, acting on cytoskeleton-associ-
ated gene expression. Finally, both disturbed insulin sign-
aling and reduced ATP induce the hyperphosphorylation
of tau. Thus, this cerebral hypometabolism may lead to
the main neuropathologic hallmarks of AD [17]: senile
plaques and neurofibrillary tangles.
Given that hypometabolism is an early and progressive
event in AD, and may precipitate downstream pathologic
events, it is reasonable to target this process as a treatment
for AD. Therefore, one therapeutic goal in AD, and other
cognitive disorders, is to improve the neuronal energy
state.BMC Neuroscience 2008, 9(Suppl 2):S16 http://www.biomedcentral.com/1471-2202/9/S2/S16
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Therapeutic approaches to hypometabolism
Attempts to improve memory performance by increasing
energy availability have met with some success in both
animal models and humans [18-20]. Because under nor-
mal circumstances the brain is largely dependent on glu-
cose, attempts have been made to increase CMRglu
directly. Facilitation of memory in AD patients occurred
when glucose levels were elevated with an oral paradigm
[21] and the hyperglycemic clamp technique [22]. These
effects may be related to the insulin response to hypergly-
cemia [23,24], because studies treating AD patients with
insulin revealed rapid effects [23]. Studies with insulin
sensitizers, such as rosiglitazone, have shown similar pos-
itive results [25]. However, because of the impracticality
of maintaining chronically elevated glucose or insulin lev-
els, and the limited ability of neurons to utilize substrates
other than glucose, an alternative energy substrate that
can be utilized by the brain to improve cognition and
memory has been explored. One such source is ketone
bodies.
Ketone bodies as treatment for central nervous system 
disorders
Ketone bodies typically provide the body with an alterna-
tive energy source when carbohydrate intake is low, as in
times of starvation. Ketone bodies consist of β-hydroxy-
butyrate (BHB), acetoacetate (ACA), and acetone. Numer-
ous studies have shown that ketone bodies are a preferred
substrate for the developing mammalian neonatal brain
[26]. Ketone bodies offer several advantages to glucose for
memory facilitation in the elderly: hyperketonemia can be
induced and sustained for many hours; ketone bodies can
cross the blood-brain barrier; and ketones are readily
metabolized by neurons.
Ketones are used by the body in a concentration-depend-
ent manner in the adult human brain, including the eld-
erly brain [27,28], until circulating concentrations reach
approximately 12 mmol/l, when they saturate the oxida-
tive machinery [29]. Ketone bodies can bypass defects in
glucose metabolism, and enter the tricarboxylic acid
cycle (TCA) cycle in the mitochondria of neurons, where
they are rapidly converted to ATP and precursors of acetyl-
choline (Figure 1).
In humans the major ketone body is BHB, and its oxida-
tion can be considered to have three major benefits: con-
version of BHB to ACA in the mitochondria generates a
reducing equivalent of NADH, which increases energy in
this redox couple [30]; conversion of ACA to acetoacetyl-
CoA generates succinate, a substrate for complex II, and
allows for possible bypass of complex I inhibition [31];
and ketone bodies increase acetyl-CoA levels in the mito-
chondria [30]. Ketone bodies may have other beneficial
nonmetabolic effects. An example is stimulation of chap-
erone-mediated autophagy [32], which may help to clear
misfolded proteins or 'neuronal traffic jams' caused by
APP dysfunction [33]. The end result of increased ketone
levels is an improvement in mitochondrial efficiency and
reduction in the generation of reactive oxygen species
[30,34].
Preclinical evidence indicates that ketone bodies can pro-
vide neuroprotective effects, showing that BHB is neuro-
protective in models of Parkinson's disease, AD, hypoxia,
and ischemia [31,35-38]. Preclinical research has also
shown positive effects of increased ketones in models of
amyotrophic lateral sclerosis [39] and glioma [40].
Clinical use of ketones to treat CNS disorders has been
ongoing for decades in the form of the ketogenic diet. This
ketogenic diet is composed mainly of fats, and induces a
decrease in blood sugar levels and an increase in ketone
bodies via conversion of fatty acids in the liver. A
ketogenic diet consisting of 88% fat, 10% protein, and 2%
carbohydrates is a valuable adjunct in the management of
epilepsy in children and adults with seizure disorder
[41,42]. In their study, Mak and coworkers [43] showed
that 53.9% of patients had a more than 75% reduction in
seizure frequency 1 month after initiation of the diet.
Recent studies have shown that children who remained
on the ketogenic diet for more than 1 year, and who had
a good response to the diet, had positive outcomes at 3-
year and 6-year follow ups [42,44]. A review of the
ketogenic diet in epilepsy was provided by VanItallie and
Nufert [28]. A clinical study in patients with Parkinson's
disease identified improvement in motor scores in
patients who showed increased ketone levels after a 28-
day ketogenic diet [45].
Ketones overcome hypometabolism Figure 1
Ketones overcome hypometabolism.
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Although the ketogenic diet and administration of other
energy substrates have shown clinical efficacy in a variety
of CNS disorders, these strategies are impractical for
chronic use because of low compliance with high fat/low
carbohydrate intake, unpalatable regimen, and poor toler-
ability to the high number of calories required to produce
therapeutic levels of ketone bodies (90% of calories must
come from fat). Therefore, a means by which to obtain
high ketone levels, while allowing the patient to eat a rel-
atively normal diet, has been under investigation.
AC-1202: a better way to elevate ketone levels
AC-1202 (Axona™; manufactured for Accera, Inc., Broom-
field, CO, USA) is a medium-chain triglyceride (MCT)
that provides a simple and safe method to induce elevated
plasma levels of ketone bodies. MCTs have chain lengths
of 5 to 12 carbons and have a different pattern of absorp-
tion and utilization than long-chain triglycerides (LCTs),
which make up 97% of dietary fats [46]. In LCT absorp-
tion, fatty acid chains are cleaved from the glycerol back-
bone by a lipase. These fatty acids form micelles, are
absorbed and re-attach as glycerol, and the resultant trig-
lycerides travel through the lymphatic system to the
bloodstream and are stored in adipose tissue. In contrast,
MCTs are absorbed without need for micelle formation
(with no storage in adipose cells) and are transported to
the liver for preferential oxidation by the portal vein [47].
The rapid oxidation of medium-chain fatty acids in the
liver can give rise to the production of ketone bodies if suf-
ficient doses of MCTs are provided. Medium-chain fatty
acids enter the mitochondria as acyl-CoA moieties, where
they undergo β-oxidation to form acetyl-CoA and ace-
toacetyl-CoA, which – if produced in excess – are com-
bined to form 3-hydroxy-3-methyl-glutaryl-CoA (HMG-
CoA). HMG-CoA is then acted on by HMG-CoA lyase to
form ACA and BHB. The liver cannot use ketone bodies
and so they are released into the circulation to be used by
other tissues (Figure 2).
The safety of human consumption of up to 1 g/kg MCTs
has been confirmed in several clinical trials. Enteral solu-
tions containing approximately 20% of the total fat calo-
ries of MCT are given in quantities of 1,000 to 3,000 ml/
day, depending on patient size and needs. Thus, under
maximum exposure conditions, patients have received 7
to 21 g/day MCTs from several months to years in total
nutrition feeding regimens This equates to 0.1 to 0.4 g/kg
body weight/day (assuming a body weight of 60 kg).
AC-1202 is an orally administered MCT that is rapidly
metabolized by the liver to the active ketone bodies BHB
and ACA, providing neurons with an alternative energy
source to glucose, regardless of the patients' carbohydrate
intake. AC-1202 has advantages over the classic ketogenic
diet because of its rapid absorption and attainment of a
ketogenic state, improved patient acceptability, and over-
all safety. The risk for ketoacidosis with AC-1202 is mini-
mal, as this results from the loss of insulin's normal
modulating effect on free fatty acids released from adipose
tissue, and on hepatic free fatty acid oxidation and
ketogenesis (production of ketone bodies). The symp-
toms of ketoacidosis are induced only when the level of
ketone bodies in the bloodstream are sustained at high
levels. Ketone bodies produced from AC-1202 are rapidly
consumed under all nutritional and physiological condi-
tions, so that sustained, high levels of ketone bodies do
not occur. Because of these advantages, we explored the
effects of AC-1202 in models of cognitive dysfunction and
in patients with cognitive disturbances.
Results
Effects of AC-1202 on canine cognition
Aged dogs exhibit an AD-like syndrome: key features in
these dogs include progressive cognitive decline and neu-
ropathologic changes that parallel those observed in
patients with AD [48]. Dogs begin to accumulate Aβ in the
prefrontal cortex at age approximately 8 years, and have
increased markers of oxidative stress in the prefrontal cor-
tex [49]. Thus, these dogs provide a suitable model for
screening the effectiveness of therapies for AD and other
cognitive dysfunctions.
We tested the hypothesis that dietary supplementation
with a canine version of AC-1202 (called AC-1203) would
improve cognitive function and alter behavioral activity in
the aged dog. Animals fed AC-1203 (2 g/kg) exhibited ele-
vated serum ketone levels, improved daytime activity,
increased performance on visual-spatial memory tasks, a
higher probability of learning an oddity task, superior per-
formance on a motor learning task, improved complex
discrimination, and increased performance in short-term
memory. There was also evidence of improved brain per-
fusion after treatment, improved blood-brain barrier
integrity, and a greater regional cerebral blood volume.
AC-1202 in patients with cognitive impairments
Three clinical trials of AC-1202 in patients with cognitive
impairments have been completed to date. These studies
have proven the hypothesis that elevation in plasma BHB
levels with an oral dose of AC-1202 can improve memory
and attention performance in individuals with memory
and cognitive impairments.
Phase 2a clinical trial in AD/mild cognitive impairment
A phase 2a trial determined the therapeutic activity of a
single dose (40 g) of AC-1202 in individuals diagnosed
with probable AD or mild cognitive impairment. A rand-
omized, crossover design was employed in 20 individuals
with a mean age of 74.7 years. A single dose of AC-1202
led to elevated BHB serum levels, which correlated posi-BMC Neuroscience 2008, 9(Suppl 2):S16 http://www.biomedcentral.com/1471-2202/9/S2/S16
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Metabolism of AC-1202 (MCTs) versus LCTs Figure 2
Metabolism of AC-1202 (MCTs) versus LCTs. MCTs are emulsifed in the gut lumen, where gastrointestinal lipases hydrolyze 
them to MCFAs. MCFAs are absorbed directly into the portal vein and, unlike LCT, are not packaged into lipoproteins. In the 
liver, MCFAs are quickly oxidized, whereas the fate of LCFAs is dependent on the metabolic state of the organism. LCFAs are 
transported to the mitochondria for oxidation using CPT1. When conditions favor fat storage, malonyl-CoA is produced as an 
intermediate in lipogenesis. Malonyl-CoA inhibits CPT1, and prevents oxidation of LCFAs in the mitochondria. MCFAs enter 
the mitochondria without the use of CPT1 and are not subject to the regulations that control the oxidation of LCFAs. Because 
MCFAs enter the liver rapidly and are quickly oxidized, a large oral dose of MCT will result in sustained hyperketonemia. CoA, 
coenzyme A; CPT1, carnitine palmitoyltransferase I; LCDG, diglyceride; LCFA, long-chain fatty acid; LCMG, long-chain 
monoglyceride; LCT, long-chain triglyceride; MCFA, medium-chain fatty acid; MCT, medium-chain triglyceride; TG, triglycer-
ide.
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tively with improvement in measures of cognition. Those
whose BHB levels were higher exhibited improved para-
graph recall with AC-1202 administration. ApoE4-nega-
tive patients exhibited significant improvement in
cognitive test scores when compared with ApoE4-positive
patients.
No adverse events (AEs) were reported with the lower
dose of MCT. Two individuals, however, experienced gas-
trointestinal distress at the higher dosage. The most prom-
inent features of these reactions were an 'unsettled
stomach' during the study visit, and diarrhea 1 to 2 days
later. The diarrhea resolved after treatment with lopera-
mide, and the lower dose was chosen for subsequent clin-
ical studies.
These preliminary findings suggest that acute elevation in
BHB levels may ameliorate the cognitive decline associ-
ated with impaired glucose metabolism in individuals
without an E4 allele. These results are consistent with
prior reports of ApoE4-related differences in insulin
metabolism and cognitive effects of insulin administra-
tion [50,51].
Phase 2b clinical trial in AD
In the second phase 2 trial, 152 patients with mild-to-
moderate AD received AC-1202 (containing 20 g MCT) or
placebo for 90 days in a double-blind, randomized design
[52]. Results from this study were consistent with those of
the earlier phase 2a study; AC-1202 produced a rapid
onset of significant improvements in cognition, as meas-
ured using AD Assessment Scale-cognitive subscale
(ADAS-cog), which were maintained throughout the
study, correlated with blood levels of BHB, and were most
apparent in ApoE4-negative patients.
Phase 2 clinical trial in age-associated memory impairment
The third trial (phase 2) explored effects of AC-1202 in
age-associated memory impairment (AAMI). AAMI is the
decline in memory that occurs during the natural course
of aging. The National Institute of Mental Health criteria
for AAMI include complaints of gradual memory loss and
everyday problems in persons more than 50 years of age.
AAMI affects an estimated 10 to 15 million people in the
USA. AAMI symptoms may be related to declines in glu-
cose metabolism in the brain that are also associated with
aging. The randomized, double-blind, placebo-control-
led, parallel, multi-center trial included 159 individuals
diagnosed with AAMI and receiving either AC-1202 (con-
taining 20 g MCT) or placebo for 90 days (Costantini LC,
Barr LJ, Vogel JL and Henderson ST, unpublished data).
Those taking AC-1202 performed significantly better on
several memory tests versus placebo. Consistent with the
findings of the phase 2a and 2b AD studies, ApoE4-nega-
tive patients responded particularly well to treatment.
Safety
In all three studies AC-1202 was well tolerated, although
greater numbers of gastrointestine-related AEs were
observed in AC-1202 recipients versus placebo. Diarrhea
was the single, most frequently reported AE in both treat-
ment groups. These gastrointestine-related AEs were
reduced when the sites were informed to reconstitute the
investigational product with a nutritional supplement
drink rather than water or juice.
Mechanism of action of AC-1202
The postulated therapeutic activity of AC-1202 is linked to
mitochondrial function. The brains of aged dogs treated
with AC-1203 were collected for mitochondrial analysis.
Mitochondria from treated animals were more bioener-
getic (they exhibited an increased capacity to phosphor-
ylate ADP to ATP), and respiration was better coupled to
ATP production. There was also evidence of decreased
mitochondrial reactive oxygen species damage [53].
A study was conducted in transgenic mice to determine
the effect of ketone bodies induced by a ketogenic diet on
behavior and Aβ deposition in the brain [54]. The mice
expressed the human 'London' APP mutation (APP/
V717I), driven by a thy-1 gene promoter. They produced
significant levels of soluble Aβ in the brain as early as 3
months of age, exhibited extensive plaque deposition by
12 to 14 months, and exhibited early behavioral deficits.
Beginning at 3 months of age, mice were fed a standard
diet (high-carbohydrate/low-fat chow) or a ketogenic
diet. Animals fed the ketogenic diet exhibited elevated
serum ketone levels and significantly reduced levels (by
about 25%) of both Aβ40 (P = 0.012) and Aβ42 (P =
0.016). The ketogenic diet fed animals also exhibited low
levels of both Aβ40 and the more amyloidic Aβ42, sug-
gesting that the ketogenic regimen either reduced process-
ing of APP or increased degradation of Aβ species. Despite
changes in ketone levels, body weight, and Aβ levels, the
ketogenic diet did not alter behavioral measures.
Conclusion
Increasing evidence suggests that dysfunction in brain glu-
cose metabolism is an early and progressive event in AD.
The hypometabolism observed in imaging studies within
relevant regions of the brain in both symptomatic AD
patients and presymptomatic, at-risk individuals, and the
correlation of this reduced glucose metabolism with dis-
ease progression suggest that improving the neuronal
energy state early in disease may influence the decline in
cognition and memory in these individuals.
Ketone bodies are an efficient alternative fuel for cells that
are unable to metabolize glucose or are 'starved' of glu-
cose. Although the ketogenic diet and administration of
other alternate energy substrates have exhibited clinicalBMC Neuroscience 2008, 9(Suppl 2):S16 http://www.biomedcentral.com/1471-2202/9/S2/S16
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efficacy in a variety of CNS disorders, these strategies are
impractical for chronic use for a variety of reasons, as dis-
cussed above.
Chronic elevation of ketone bodies has been shown to be
safe in humans, as demonstrated by decades of use in
refractory epilepsy patients [41,43,44]. MCTs have been in
human use for several years and are considered GRAS
(generally recognized as safe) by the US Food and Drug
Administration. They are metabolized differently from
LCTs because of their different physical characteristics.
Other products on the market containing MCTs are used
therapeutically for the dietary management of conditions
such as malnutrition, fat malabsorption, short bowel syn-
drome, and other conditions.
Oral AC-1202 was designed to elevate serum ketone levels
safely and efficiently, regardless of carbohydrate status of
the diet. We have shown that AC-1202 improves memory
and cognition in patients with mild-to-moderate AD [51]
and in AAMI.
The effects of AC-1202 were more marked in the ApoE4-
negative subpopulation, supporting previous findings
that there are metabolic differences between E4-positive
and E4-negative AD. This suggests that AD patients with
varying ApoE genotypes may have different dose-response
patterns, or that the differences between ApoE genotypes
reflect differences in pathophysiology or stage of disease.
A strong ApoE4 effect has also been seen with other AD
treatments. In a study of tacrine, 80% of ApoE4-negative
AD patients improved relative to baseline, whereas 60%
of ApoE4-positive patients declined [55]. However, subse-
quent studies of other acetylcholinesterase inhibitors have
failed to replicate these findings [56].
AD treatments in development that target glucose/insulin
signaling have demonstrated benefits exclusively in E4-
negative subjects. Craft and coworkers [50] demonstrated
improvement in cognitive tests in mild-to-moderate
ApoE4-negative AD patients when they were infused with
glucose and insulin. Treatment with nasal insulin demon-
strated improvement in cognitive performance in 15 min-
utes only in E4-negative patients [57]. Recently, in a large,
placebo-controlled study, the insulin-sensitizing agent
rosglitazone exhibited efficacy only in E4-negative
patients [25].
Ketone bodies provide an alternate energy source for
hypometabolic neurons, and may offer a novel treatment
for AD as well as other neurodegenerative disorders that
are characterized by neuronal hypometabolism. The
results from studies with AC-1202 indicate that patients
exhibit cognitive improvements in response to elevation
of ketone levels, and support data linking AD to glucose/
insulin metabolism.
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